论文部分内容阅读
目的:对阿奇霉素治疗支气管哮喘的疗效及安全性进行研究。方法:选取我院在2016年9月-2017年9月确诊为支气管哮喘的患者60例,运用随机数表法将患者分为实验组(32例)和对照组(28例),对照组及实验组患者分别使用舒喘灵气雾剂、阿奇霉素进行治疗,在疗程结束后对两组患者治疗效果及不良反应发生率进行对比分析。结果:在经过两周治疗后,实验组患者显效例数,有效例数,无效例数分别为29例、2例和1例,治疗总有效率为96.88%;对照组患者显效例数,有效例数,无效例数分别为17例、4例和7例,治疗总有效率为75.00%,对照组患者治疗总有效率明显低于实验组,并且P<0.05,差异较为显著,存在统计学意义;实验组患者不良反应总例数为2例,发生率为9.38%;对照组患者不良反应总例数为8例,发生率为28.57%,由以上数据可知实验组患者出现不良反应的几率较对照组小(P<0.05),具有统计学意义。结论:阿奇霉素治疗支气管哮喘的临床疗效较好,并且具有较高的安全性,患者不良反应发生率较小,具有一定的临床推广价值。
Objective: To study the efficacy and safety of azithromycin in the treatment of bronchial asthma. Methods: Sixty patients with bronchial asthma diagnosed in our hospital from September 2016 to September 2017 were selected. Patients were divided into experimental group (32 cases) and control group (28 cases) by random number table method and control group Patients in the experimental group were treated with Shu Chuan Ling aerosol and azithromycin respectively. After treatment, the therapeutic effect and incidence of adverse reactions in the two groups were compared and analyzed. Results: After two weeks of treatment, the number of effective cases, effective cases and invalid cases in experimental group were 29 cases, 2 cases and 1 case, respectively. The total effective rate was 96.88%. In the control group, the effective cases were effective The number of cases, the number of invalid cases were 17 cases, 4 cases and 7 cases, the total effective rate was 75.00%, the control group, the total effective rate was significantly lower than the experimental group, and P <0.05, the difference was significant, there is statistical The total number of adverse reactions in the experimental group was 2 cases, the incidence rate was 9.38%; the total number of adverse reactions in the control group was 8 cases, the incidence was 28.57%, from the above data we can see the incidence of adverse reactions in the experimental group patients Smaller than the control group (P <0.05), with statistical significance. Conclusion: The clinical efficacy of azithromycin in the treatment of bronchial asthma is good, and has high safety. The incidence of adverse reactions in patients is small, and has some clinical promotion value.